Sinus node disease in subjects with type 1 ECG pattern of Brugada syndrome  by Letsas, Konstantinos P. et al.
OS
K
R
S
a
b
c
d
e
a
A
R
R
2
A
A
K
B
S
P
I
I
t
a
T
ﬁ
o
i
(
m
g
I
e
T
0
hJournal of Cardiology 61 (2013) 227–231
Contents lists available at SciVerse ScienceDirect
Journal  of  Cardiology
jo u r n al hom epage: www.elsev ier .com/ locate / j j cc
riginal  article
inus  node  disease  in  subjects  with  type  1  ECG  pattern  of  Brugada  syndrome
onstantinos  P.  Letsas  (MD)a,b,∗, Panagiotis  Korantzopoulos  (MD,  PhD)c, Michael  Efremidis  (MD)a,
einhold  Weber  (MD)b,  Louiza  Lioni  (MD)a, George  Bakosis  (MD)a, Vassilios  P.  Vassilikos  (MD,  PhD)d,
pyridon  Deftereos  (MD)e,  Antonios  Sideris  (MD)a, Thomas  Arentz  (MD,  PhD)b
Second Department of Cardiology, Evangelismos General Hospital of Athens, Greece
Arrhythmia Service, Herz-Zentrum, Bad Krozingen, Germany
Department of Cardiology, University Hospital of Ioannina, Greece
First Department of Cardiology, AHEPA University Hospital of Thessaloniki, Greece
Department of Cardiology, “G. Gennimatas” General Hospital of Athens, Greece
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 11 October 2012
eceived in revised form
2 November 2012
ccepted 4 December 2012
vailable online 9 February 2013
eywords:
rugada syndrome
inus node disease
acemaker
mplantable cardioverter deﬁbrillator
a  b  s  t  r  a  c  t
Background:  The  spectrum  of  phenotypes  related  to mutations  of  the  SCN5A  gene include  Brugada  syn-
drome (BS),  long  QT  syndrome,  progressive  cardiac  conduction  defect,  and  sinus  node  disease  (SND).  The
present  study  investigated  the  incidence  of SND  in  subjects  with  type  1 electrocardiogram  (ECG)  pattern
of BS.
Methods  and  results:  The  study  population  consisted  of 68  individuals  (55 males,  mean  age  44.8  ± 12.8
years)  with  spontaneous  (n  =  27)  or drug-induced  (n = 41)  type  1 ECG  pattern  of BS. Twenty-eight  subjects
were  symptomatic  with  a history  of  syncope  (41.2%).  SND  was  observed  in  6  symptomatic  subjects  (8.8%),
and  was  mainly  attributed  to  sino-atrial  block  with  sinus  pauses.  Two patients  were  initially  diagnosed
with  SND,  and  received  a pacemaker.  Patients  with  SND  displayed  an  increased  P-wave  duration  in  leads
II and  V2, PR  interval  in  leads  II and  V2,  QRS  duration  in  leads  II and V2, and  increased  QTc  interval  in lead
V2 (p  <  0.05).  AH  and  HV  intervals  as  well  as  corrected  sinus  node  recovery  time  (cSNRT)  were  signiﬁcantly
prolonged  in  subjects  with  SND  (p  <  0.05).  During  a mean  follow-up  period  of  5.0 ±  3.6 years,  ﬁve subjects
with  a  history  of syncope  suffered  appropriate  implantable  cardioverter  deﬁbrillator  (ICD)  discharges  due
to  ventricular  arrhythmias  (7.4%).  None  of those  diagnosed  with  SND  suffered  syncope  or  ICD  therapies.
Conclusion:  SND  is  not  an  uncommon  ﬁnding  in  subjects  with  type  1 ECG pattern  of  BS. The occurrence
of  SND  in  relatively  young  patients  may  deserve  meticulous  investigation  including  sodium  channel
3  Jap
blocking  test.
©  201
ntroduction
The Brugada syndrome (BS) is an arrhythmogenic entity that
ypically manifests with syncope or cardiac arrest due to ventricular
rrhythmias in individuals with structurally normal hearts [1–4].
he SCN5A gene encoding for the cardiac sodium channel was the
rst gene linked to BS [2]. Apart from BS, the spectrum of phen-
types related to mutations of the -subunit of the SCN5A gene
nclude long QT syndrome, progressive cardiac conduction defect
Lenègre syndrome), atrioventricular (AV) block, atrial arrhyth-
ias, and sinus node disease (SND) [5–7].
It has been reported that the loss of function of single SCN5A
ene mutations can be responsible for both BS and SND [8,9].
n previous case studies, the diagnostic type 1 electrocardiogram
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(ECG) pattern of BS was  identiﬁed after pacemaker implantation
for SND [10–15].  SND may  be implicated in the pathophysiology of
ventricular arrhythmic events in BS, since bradycardia-dependent
augmentation of ST-elevation has been previously demonstrated in
patients with BS [16]. The coexistence of SND and BS raises severe
diagnostic and therapeutic dilemmas in symptomatic subjects, par-
ticularly in the case where SND is the initial diagnosis. Patients
with symptomatic SND are typically treated with pacemaker (PM)
implantation, while an implantable cardioverter deﬁbrillator (ICD)
is currently indicated in symptomatic patients with BS [17]. The
present study investigated the incidence and the prognostic signif-
icance of SND in patients with type 1 ECG pattern of BS.
MethodsPatient population
The clinical records of consecutive individuals diagnosed
with spontaneous or drug-induced (ajmaline 1 mg/kg, ﬂecainide
vier Ltd. All rights reserved.
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 mg/kg, procainamide 10 mg/kg) type 1 ECG pattern of BS from
999 to 2011 were retrospectively analyzed. The ECG diagnosis of
S was strictly based on the recommendations of the Second Con-
ensus Conference on BS [2]. All subjects underwent transthoracic
chocardiography in order to rule out the presence of structural
eart disease including myocardial ischemia. Laboratory tests were
erformed to exclude any electrolyte or metabolic disturbances
ncluding thyroid dysfunction. Subjects with established neurally
ediated syncope were excluded from the study. The following
linical data were collected in all patients: age, gender, family his-
ory of sudden cardiac death (SCD) (<45 years of age), family history
f BS, and history of atrial tachyarrhythmias. Screening for SCN5A
ene mutations was performed in selected cases. Subjects with
 previous history of syncope or aborted SCD were classiﬁed as
ymptomatic.
Baseline 12-lead ECGs were recorded at a paper speed of 25 or
0 mm/s  and an ampliﬁcation of 10 mm/mV.  The following parame-
ers were reviewed in the absence of antiarrhythmic medication: (i)
he P-wave duration in leads II and V2; (ii) the PR duration in leads
I and V2; (iii) the QRS duration in leads II and V2; and (iv) the QTc
nterval in leads II and V2 (corrected using Bazett’s formula). ECG
easurements were performed by two independent cardiologists.
hen measurements were not identical, the mean of the values
ere calculated. To avoid diurnal variation, ECGs performed during
he same time interval (09.00–12.00 h) were evaluated. The inter-
bserver and intraobserver variability was less than 5%. Ambulatory
4 or 48 h Holter ECG recordings were evaluated in all subjects.
An electrophysiological study (EPS) was carried out in selected
ases based on the judgment of the treating physician. The base-
ine AH and HV intervals were measured. The corrected sinus
ode recovery time (cSNRT) was calculated following burst atrial
acing at different cycle lengths. A cSNRT of more than 550 ms
as considered abnormal. Programmed right ventricular stimu-
ation was performed at three running cycle lengths (600, 500,
nd 430 ms)  with up to triple extrastimuli (minimum coupled
xtrastimuli of 200 ms). Inducible ventricular arrhythmia was
eﬁned as ventricular tachycardia/ﬁbrillation (VT/VF) lasting >30 s,
ausing syncope/circulatory collapse, or requiring intervention to
e terminated. The study was approved by the medical ethical
eview committee of the participating centers. Informed consent
as obtained from all patients.
eﬁnition of sinus node disease
SND was deﬁned when one of the following was  present: (i)
inus bradycardia <40 beats/min while awake; (ii) sino-atrial block
r sinus arrest with pauses >3 s; (iii) bradycardia–tachycardia syn-
rome deﬁned as episodes of atrial tachyarrhythmias coexisting
ith sinus bradycardia, sino-atrial block, or sinus arrest; and (iv)
SNRT >550 ms  at EPS in previously symptomatic patients (syncope
r dizziness).
tatistical analysis
All continuous variables had a normal distribution, according
o Shapiro–Wilk’s corresponding test. All continuous data are pre-
ented as mean ± standard deviation, while categorical variables
re reported as absolute and relative (percentages) frequencies.
ifferences in categorical variables were evaluated using Pearson’s
hi-square or Fisher’s exact test. Student’s t-test was used for com-
arison of continuous variables. All reported probability values
p-values) were based on two-sided tests and compared to a signif-
cance level of 0.05. Data were analyzed using SPSS.17 for Windows
SPSS, Chicago, IL, USA).iology 61 (2013) 227–231
Results
The study population consisted of 68 individuals (55 males,
mean age 44.8 ± 12.8 years) with spontaneous (n = 27) or drug-
induced (n = 41) type 1 ECG pattern of BS. All subjects displayed
a structurally normal heart. Twenty-eight subjects were symp-
tomatic with a history of syncope (41.2%), and 18 displayed
a positive family history of BS and/or sudden cardiac death
(26.5%). EPS was performed in 37 subjects, and programmed right
ventricular stimulation induced VT/VF in 25 of them (67.5%).
There were no signiﬁcant differences between subjects with and
without spontaneous type 1 ECG pattern regarding the cSNRT
(640.00 ± 763.54 vs. 403.33 ± 370.91, p = 0.543), AH (104.58 ± 33.81
vs. 102.26 ± 34.61, p = 0.863), and HV intervals (55.27 ± 10.98 vs.
49.40 ± 16.05, p = 0.279). Genetic test was  performed in 6 subjects
(one with SND), and identiﬁed one positive proband without SND
(exon 26, 4477–4479delAAG, K1493del). An ICD was implanted in
28 individuals (41.1%).
SND was observed in 6 subjects (8.8%). All subjects with SND
were symptomatic. The clinical data of these individuals are
depicted in Table 1. Four patients exhibited sino-atrial block with
sinus pauses >3 s (Figs. 1 and 2), and two patients displayed sinus
bradycardia <40 beats/min while awake. Two  of them received a
dual-chamber PM (lower rate of 60 beats/min), while the other four
a dual-chamber ICD (lower rate of 60 beats/min). The patients who
received a PM were initially diagnosed as having SND, while the
diagnostic Brugada ECG phenotype was unmasked after sodium
channel blocking test with ajmaline during follow-up. An ICD
upgrade was offered in both patients. As shown in Table 2, sub-
jects with SND displayed an increased P-wave duration in leads II
(p < 0.001) and V2 (p = 0.009), PR interval in leads II (p < 0.001) and
V2 (p = 0.009), QRS duration in leads II (p = 0.036) and V2 (p = 0.001),
and increased QTc interval in lead V2 (p = 0.009). AH (p < 0.001) and
HV (p = 0.011) intervals as well as cSNRT (p = 0.027) were signiﬁ-
cantly prolonged in subjects with SND. Fourteen subjects suffered
atrial tachyarrhythmias (20.5%), mainly atrial ﬁbrillation. Although
not statistically signiﬁcant, subjects with SND displayed a higher
rate of atrial ﬁbrillation or atrial ﬂutter in relation to those without
SND (50% vs. 17.7%, p = 0.062).
During a mean follow-up period of 5.0 ± 3.6 years, ﬁve previ-
ously symptomatic subjects suffered appropriate ICD discharges
due to ventricular arrhythmias (7.4%), and one died due to non-
cardiac causes. None of those diagnosed with SND suffered syncope
or ICD therapies. None of the asymptomatic individuals had syn-
cope or ICD therapies. There were no inappropriate ICD therapies
in our cohort. Two complications related to the implantation pro-
cedure were noted (one pneumothorax and one pocket infection).
Discussion
The main ﬁndings of the present study are as follows: (i) the
incidence of SND in subjects with type 1 ECG phenotype of BS is
comparatively high given the relative young age of this population
and (ii) subjects with BS phenotype and SND display prolonged
P-wave duration, PR interval, QRS duration, and QTc interval com-
pared to those without SND.
Sodium channels play an important role in pacemaking of the
heterogeneous sinus nodal tissue [18]. SCN5A gene mutations lead
to loss of function of the cardiac sodium current, resulting in
reduced action potential upstroke velocity and slowed impulse
propagation [8]. Two different mechanisms have been suggested
to underlie SND due to SCN5A gene mutations: (i) a slowed con-
duction between the sino-atrial node and the atria, due to an
increased stimulus threshold in the atrial myocardium and (ii) a dis-
order of the sino-atrial node itself; although predominantly calcium
K.P. Letsas et al. / Journal of Cardiology 61 (2013) 227–231 229
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Fig. 1. Ambulatory monitoring showing several episodes of sinus arrest (patient 2).
currents are responsible for the action potential upstroke in sino-
atrial and atrioventricular nodal cell, sodium channels also play
a signiﬁcant role in pacemaking of the heterogeneous sino-atrial
nodal tissue [18]. Experimental studies in heterozygous SCN5A
knockout mice have shown that SND attributed to sodium current
reduction involves reduced automaticity, and conduction slowing
or blocking of action potentials from the sino-atrial node to the
surrounding atrial muscle [19].
Previous studies have indicated that single SCN5A gene muta-
tions can be responsible for both BS and SND. In a previous
study, among 38 patients clinically diagnosed with BS, heterozy-
gous SCN5A gene mutations were identiﬁed in 4 subjects. All of
them had bradyarrhythmic complications including three with
SND and one with paroxysmal complete atrioventricular block.
None of these probands had additional SCN5A mutations, sug-
gesting that this type of “loss of function” overlap syndrome (BS
plus SND/atrioventricular block) may  result from a single SCN5A
mutation [9].  Morita et al. have shown that sinus node function is
impaired in patients with Brugada ECG pattern and inducible ven-
tricular ﬁbrillation at EPS compared with those without inducible
arrhythmias. In this study, abnormal values of cSNRT occurred in 6%
of patients without induced arrhythmias and 31% of patients with
induced VT/VF [13]. Sumiyoshi et al. reported 3 patients with symp-
tomatic BS and documented sinus pauses >3 s. EPS demonstrated
prolonged SNRT in 2 patients, and a PM was  initially implanted
before the diagnosis of BS [14]. In the study of Bordachar et al., the
incidence of SND (diurnal heart rate <55 beats/min and prolonged
cSNRT >525 ms)  in patients with BS was  17% [20]. In a retrospective
analysis, among 487 patients diagnosed with SND, BS ECG phe-
notype was found in 14 patients (2.87%) including 4 (0.82%) with
type 1 and 10 (2.05%) with type 2. During follow-up, 2 out of the
4 patients with type 1 ECG pattern experienced a VT/VF episode
[21]. Spontaneous augmentation of ST-segment elevation in daily
life has been described along with an increase in vagal activity in BS
patients [22]. A circadian variation of ﬂuctuation in ST-segment ele-
vation has been demonstrated, and ST-segment elevation always
becomes prominent just before VT/VF episodes [23]. In BS, VT/VF
and sudden cardiac death mainly occur in the resting state, predom-
inantly during sleep [24]. Previous studies have also demonstrated
a rate dependence of both the J-wave amplitude and ST-segment
elevation [25]. These phenomena could be caused by a slow recov-
ery from the inactivation of the Ito current [26]. Sino-atrial block
with sinus pauses or sinus bradycardia may  therefore lead to aug-
mentation of the ST-segment elevation and VT/VF events. Thus, the
possibility of SND should be taken into consideration in patients
with BS.
230 K.P. Letsas et al. / Journal of Cardiology 61 (2013) 227–231
Fig. 2. Electrocardiographic tracing (25 mm/s) and endocardial signals from the high right atrium and the His-bundle region showing a spontaneous episode of sinus arrest
during  electrophysiological study (patient 6). HRA, high right atrium electrogram recorded from proximal bipole; HRA STIM, high right atrium electrogram recorded from
distal  bipole (used for stimulation); HBED, His-bundle electrogram recorded from the distal bipole; HBEP, His-bundle electrogram recorded from the proximal bipole.
Table  2
Clinical, electrocardiographic and electrophysiological data of subjects with and without SND.
Variables Subjects with SND (n = 6) Subjects without SND (n = 62) p-Value
Age (years) 43.16 ± 6.82 44.93 ± 13.23 0.749
Males  (n) 3 (50%) 52 (83.9%) 0.044
History of syncope (n) 6 (100%) 22 (35.5%) 0.002
Family history of BS/SCD (n) 2 (33.3%) 16 (25.8%) 0.690
Spontaneous ECG type 0.721
Type  1 (n) 2 (33.3%) 25 (40.3%)
Type 2 (n) 3 (50%) 21 (33.9%)
Type 3 (n) 1 (16.7%) 16 (25.8%)
P-wave duration in lead II (ms) 148.33 ± 31.25 113.25 ± 17.04 <0.001
P-wave duration in lead V2 (ms) 110.00 ± 24.49 90.73 ± 16.01 0.009
PR  interval in lead II (ms) 231.66 ± 44.90 174.35 ± 28.45 <0.001
PR  interval in lead V2 (ms) 219.16 ± 48.82 164.11 ± 26.77 0.009
QRS  in lead II (ms) 119.16 ± 13.57 101.20 ± 20.07 0.036
QRS  in lead V2 (ms) 131.66 ± 12.11 109.67 ± 15.59 0.001
QTc  in lead II (ms) 423.13 ± 42.77 408.32 ± 30.35 0.275
QTc  in lead V2 (ms) 463.18 ± 45.88 417.31 ± 39.49 0.009
EPS  (n) 5 (83.3%) 32 (51.6%) 0.136
AH  interval (ms) 154.80 ± 30.90 89.76 ± 19.66 <0.001
HV  interval (ms) 65.80 ± 18.79 48.57 ± 11.00 0.011
cSNRT (ms) 1366.66 ± 550.75 283.33 ± 15.27 0.027
Inducible VT at EPS (n) 2 (40%) 23 (65.4%) 0.267
ICD  implantation (n) 4 (66.6%) 24 (38.7%) 0.184
PM  implantation (n) 2 (33.3%) 0 (0%) <0.001
Atrial  arrhythmias during follow-up (n) 3 (50%) 11 (17.7%) 0.062
Ventricular arrhythmic events during follow-up (n) 0 (0%) 5 (8.1%) 0.470
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In the present report, we showed that a signiﬁcant number
f subjects with type 1 ECG pattern of BS display SND (8.8%).
he most common cause of SND in these patients was sino-atrial
lock leading to sinus pauses >3 s. Two of these patients were
nitially diagnosed with SND, and received a PM.  These patients
emained asymptomatic during a long-term follow-up period (25
nd 7 years, respectively). SND may  be the predominant pheno-
ype in these patients, a fact that may  explain their benign clinical
ourse [27]. Another possible explanation is that cardiac pacing
lower rate of 60 beats/min) may  protect these patients from severe
radycardia that could induce augmentation of the ST-segment
levation and VT/VF events [22–25].  Based on the current recom-
endations, an ICD should be implanted in symptomatic patients
ith the diagnostic ECG of BS [2].  In our study, an upgrade to an
CD was offered in both patients who initially received a PM.  Wecardiogram; EPS, electrophysiological study; cSNRT, corrected sinus node recovery
aker.
additionally showed that subjects with type 1 ECG pattern of BS and
SND display increased P-wave duration and PR interval. Further-
more, cSNRT was abnormal in all cases with SND who  underwent
an EPS. Previous studies have shown that patients with BS display
an increased P-wave duration and PR interval, particularly those
with an SCN5A gene mutation [28,29].  These ﬁndings suggest that
the reduced sodium current and the intra-atrial conduction veloc-
ity possibly underlie the mechanisms of increased P-wave duration
and PR interval in patients with BS. In addition, the PROSPER study
has demonstrated that prolonged P-wave duration and PR inter-
val provides signiﬁcant information on the risk of developing atrial
ﬁbrillation [30]. In our study, a trend toward a higher rate of
atrial arrhythmias was observed in subjects with SND. SND is often
associated with atrial tachyarrhythmias (tachy–brady syndrome)
[31,32]. Fibrotic atrial cardiomyopathy may  be the underlying
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athophysiology even in the young subjects with SND and atrial
rrhythmias [32]. Morimoto et al. reported an autopsy case of BS
ith signiﬁcant lesions in the sinus node, including reduction of the
odal cells and ﬁbrosis [15]. Subjects with BS ECG pattern and SND
xhibited increased QRS duration and QTc interval compared to
hose without SND, an event that possibly reﬂects an advanced elec-
rical disease. However, none of those diagnosed with SND suffered
yncope or ICD therapies.
imitations
The present study has several limitations. First, it is a retrospec-
ive analysis and hence is subject to the limitations inherent in any
etrospective study. Second, a small number of subjects with SND
ere studied. Third, chronotropic incompetence which is a mani-
estation of SND was not evaluated. Fourth, EPS was  not performed
n all subjects. Finally, screening for SCN5A gene mutations was
erformed in only 6 subjects.
onclusions
SND is not an uncommon ﬁnding in subjects with type 1
CG phenotype of BS. The occurrence of SND in relatively young
atients is puzzling, and deserves meticulous investigation includ-
ng sodium channel blocking test. In patients with SND and Brugada
ign who display recurrent arrhythmogenic syncope following PM
mplantation, an upgrade to an ICD should be offered. The progno-
tic signiﬁcance of SND in BS should be evaluated in prospective
tudies.
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